VGX 3100

Drug Profile

VGX 3100

Alternative Names: Human papillomavirus vaccine-VGX Pharmaceuticals; VGX-3100

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals
  • Class Cancer vaccines; DNA vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cervical intraepithelial neoplasia
  • Phase II Human papillomavirus infections; Vulvar intraepithelial neoplasia
  • Clinical Phase Unknown Head and neck cancer

Most Recent Events

  • 02 Jan 2018 Inovio enters into an amended license and collaboration agreement with ApolloBio to develop and commercialise VGX-3100 in Greater China (China, Hong Kong, Macao, Taiwan)
  • 29 Nov 2017 Inovio Pharmaceuticals plans a phase II proof-of-concept trial for high grade anal neoplasia (caused by HPV) in 2018
  • 29 Nov 2017 Pharmacodynamics data from a phase IIb trial in Cervical intraepithelial neoplasia and Human papillomavirus infections released by Inovio Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top